Brief: Atea Pharmaceuticals Announces Chugai In-License Of AT-527 From Roche For The Treatment Of COVID-19 In Japan
19/02/2021 13:54
Feb 19 (Reuters) - Atea Pharmaceuticals Inc AVIR.O :
* ATEA PHARMACEUTICALS ANNOUNCES CHUGAI IN-LICENSE OF AT-527
FROM
ROCHE FOR THE TREATMENT OF COVID-19 IN JAPAN
* ATEA PHARMACEUTICALS, INC. - ROCHE AND ATEA ARE JOINTLY
DEVELOPING AT-527 FOR TREATMENT OF COVID-19
* ATEA PHARMACEUTICALS, INC. - ROCHE HAS RIGHT TO
COMMERCIALIZE
AT-527 OUTSIDE OF UNITED STATES
Source text for Eikon: ID:nGNX3nY0ff
Further company coverage: AVIR.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Chugai Pharmaceutical
See all newsRegarding Discontinuation Of Development Of Gym329 (Emugrobart) For Obesity, Return Of License And Resumption Of Development For SMA
Table: Chugai Pharm 6-MTH group results (IFRS)
Japan's Nikkei roars past 62,000 on earnings, Middle East optimism; JGBs rally (updated)
Japan's Nikkei surges past 61,000 for first time on earnings, Mideast optimism
Japan's Nikkei closes above 60,000 for first time on earnings optimism (updated)